BNTX250117C260000
- 0.66
- 0.000.00%
BioNTech Newsroom
Wall Street Analysts Predict a 25.59% Upside in BioNTech (BNTX): Here's What You Should Know
US MOVERS&SHAKERS Jan 13-Jan 17, 2025
Truist Financial Maintains BioNTech(BNTX.US) With Buy Rating
BofA Securities Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $150
Goldman Sachs Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $137
Bank of America Securities Keeps Their Buy Rating on BioNTech SE (BNTX)
BioNTech Provides Business and Pipeline Updates
BioNTech Initiates Global Clinical Trials for BNT327/PM8002 Combinations and Advances MRNA Cancer Immunotherapy Strategies
Express News | BioNTech SE - for 2025, Co & Pfizer Expect Largely Stable Vaccination Rates & Market Share in U.S. and Revenue Phasing Similar to 2024
BioNTech Shares Pipeline Advances, Including MRNA Cancer Immunotherapies And Combination Therapies, At J.P. Morgan Healthcare Conference
Why BioNTech (BNTX) Shares Are Volatile Today
Express News | Shares of Vaccine Stocks Are Trading Lower After Moderna Issued 2025 Revenue Guidance Below Analyst Estimates
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
Truist Financial Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $172
BioNTech Analyst Ratings
Truist Financial Initiates BioNTech(BNTX.US) With Buy Rating, Announces Target Price $172
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading